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Introduction:  Given  the  biological  complexity  of  the  ageing  process,  there  is  no  single, simple  and  reliable
measure  of how  healthily  someone  is ageing.  Intervention  studies  need  a panel  of  measures  which  capture
key  features  of healthy  ageing.  To  help  guide  our research  in this  area,  we  have  adopted  the  concept  of
the  “Healthy  Ageing  Phenotype”  (HAP)  and  this  study  aimed  to (i) identify  the most  important  features
of  the  HAP  and (ii) identify/develop  tools  for  measurement  of those  features.
Methods:  After  a comprehensive  assessment  of the literature  we  selected  the  following  domains:  physio-
logical  and  metabolic  health, physical  capability,  cognitive  function,  social  wellbeing,  and  psychological
wellbeing  which  we hoped  would  provide  a reasonably  holistic  characterisation  of  the  HAP.  We  reviewed
the  literature  and  identified  systematic  reviews  and/or  meta-analysis  of  cohort  studies,  and  clinical  guide-
lines  on  outcome  measures  of  these  domains  relevant  to the  HAP.  Selection  criteria  for these  measures
included:  frequent  use  in  longitudinal  studies  of  ageing;  expected  to  change  with  age;  evidence  for  strong
association  with/prediction  of  ageing-related  phenotypes  such  as  morbidity,  mortality  and  lifespan;
whenever  possible,  focus  on studies  measuring  these  outcomes  in  populations  rather  than  on  individuals
selected  on  the  basis  of  a  particular  disease;  (bio)markers  that  respond  to (lifestyle-based)  intervention.
Proposed  markers  were  exposed  to critique  in a Workshop  held  in Newcastle,  UK  in October  2012.
Results:  We  have  selected  a  tentative  panel  of (bio)markers  of physiological  and  metabolic  health,  physical
capability,  cognitive  function,  social  wellbeing,  and psychological  wellbeing  which  we  propose  may  be
useful  in  characterising  the HAP  and  which  may  have  utility  as  outcome  measures  in  intervention  studies.
In addition,  we have  identified  a  number  of  tools  which  could  be  applied  in community-based  intervention
studies  designed  to  enhance  healthy  ageing.
Conclusions:  We  have  proposed,  tentatively,  a panel  of  outcome  measures  which  could  be  deployed
in  community-based,  lifestyle  intervention  studies.  The  evidence  base  for selection  of measurement
domains  is  less  well  developed  in some  areas  e.g. social  wellbeing  (where  the  definition  of  the  con-
cept  itself  remains  elusive)  and this  has implications  for the  identification  of  appropriate  tools.  Although
we  have  developed  this  panel  as potential  outcomes  for intervention  studies,  we recognise  that  broader
agreement  on the concept  of  the  HAP and  on tools  for its  measurement  could  have  wider utility and  e.g.
could  facilitate  comparisons  of
© 2013 The A
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. Introduction
For many people, longer life is associated with more years of
oor health. Indeed, much of humankind’s experience of ill-health
nd expenditure on medical and social care (especially in Western
ountries) are concentrated in the later years of life [1]. The chal-
enge is to find ways of improving health and maintaining wellbeing
hroughout the life-course.
There is very good evidence that behavioural factors (notably
moking, diet, alcohol consumption and physical activity) and
ocial factors (including roles, relationships and support) are
trongly associated with health and wellbeing in later life [2,3].
owever, there is very little evidence about the long-term efficacy
f practical, lifestyle-based interventions to change these factors
nd thereby promote health and wellbeing in later life. In addition,
valuating the efficacy of such interventions is limited by the lack
f appropriate outcome measures. Most of the existing tools for
easuring change in health and wellbeing in response to inter-
entions have not been developed or validated for use in older
ndividuals and many are focussed on disease or disability rather
han on healthy ageing.
Given the biological complexity, and the heterogeneity, of the
geing process, it is highly unlikely that any single measure will
e capable of capturing reliably healthy ageing at the level of the
ndividual. So, in intervention studies, especially lifestyle-based
ntervention studies such as those that we are developing in the
iveWell Programme,1 we  need a panel of measures which cap-
ure key features of healthy ageing (Fig. 1). To help guide our
esearch in this area, we have adopted the concept of the “Healthy
geing Phenotype” (HAP) which is intended to encapsulate the
bility to be socially engaged, productive and to function indepen-
ently both at physical and cognitive levels. A Spark Workshop
onvened by Unilever and the Medical Research Council UK sug-
ested that the HAP may  be defined as the condition of being
live, while having highly preserved functioning metabolic, hor-
[4]. The Workshop on which the present Report is based aimed
to address this research gap by (i) identifying the most impor-
tant features of the HAP and (ii) identifying or developing tools
for measurement of those features specifically in the context of
community-based intervention studies. Although we had specific
aims for the Workshop in respect of tools for measuring outcomes
in intervention studies, the work that we have done on conceptual-
isation of the HAP and on tools for its measurement may have wider
utility. For example, adoption of common measures for “healthy
ageing” could facilitate comparisons across diverse studies and
populations and with a range of study designs.
This Workshop held in October 2012 in Newcastle, UK involved
approximately 50 professionals from complementary disciplines
including Physiology, Medicine, Nutrition, Epidemiology, Physi-
cal activity, Movement and Rehabilitation, Geriatrics, Gerontology,
Psychology, and Social Sciences. Ageing is a complex process with
many definitions [5] and, for pragmatic reasons, the Workshop con-
sidered five HAP domains: (1) physiological and metabolic health,
(2) physical capability, (3) cognitive function, (4) psychological
wellbeing, and (5) social wellbeing. After a critical analysis of cur-
rent evidence on the characterisation of healthy ageing, we decided
to focus on specific functional biomarkers (where possible) in each
of these 5 domains. Potential measurements in each of the domains
were proposed in a presentation by a member of the organis-
ing panel and critiqued by an invited “Discussant” before further
discussion by the rest of the group. We  prioritised identification
of those features of the particular domain which are associated
most strongly with “healthy ageing” and, where possible, identi-
fied (validated) tools for measuring those features. In this report
we summarise the outcomes of the workshop in each of the areas
covered (Fig. 2).
Our aim is to establish a minimum set of (bio)markers to assess
relevant processes associated with the ageing process which can
be used holistically to quantify the HAP. For this purpose, weonal and neuro-endocrine control systems at the organ, tissue
nd molecular levels [4]. However, as yet, there is no agreed defi-
ition of the HAP and no consensus on how it should be measured
1 LiveWell is a research programme intended to develop interventions to enhance
ealth and well-being in later life. LiveWell focuses on the retirement period
defined as 55–70 years of age) as a window of opportunity for successful inter-
ention. http://www.livewell.ac.uk.focused on objectively assessed outcomes and biomarkers com-
monly used in population studies which are potentially applicable
in community-based intervention studies, expected to change with
age, capable of predicting ageing-related phenotypes (e.g. morbid-
ity, mortality, Quality of Life (QoL), Health span), and amenable to
modification by lifestyle interventions. We  recognise that our work
is limited by conceptual and practical problems. In particular, we
are trying to measure something (healthy ageing) which has yet
to be defined adequately and, as a consequence, we have had to
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. Biomarkers of physiological and metabolic health
One of the current theories of ageing proposes that the age-
ng phenotype results from accumulated molecular damage [6]
ue to stochastic events and the effects of chronic exposure to
tressors (e.g. smoking, obesity, or physical inactivity). A grad-
al loss of the homeostatic mechanisms necessary to maintain
issue function and physiological capacity is thus a hallmark of
geing [7,8]. Such loss may  translate eventually into metabolic
ysregulation leading to the development of early signs and
ymptoms of disease or pre-disease which, if not identified and
anaged, will eventually result in functional loss, chronic dis-
ase and finally death. Therefore, biomarkers of physiological
nd metabolic processes are potentially useful measures within
he HAP which may  be responsive to lifestyle-based interven-
ions.
We  searched the literature for systematic reviews and meta-
nalysis on objectively assessed physiological and metabolic
iomarkers in relation to healthy ageing and reviewed evidence
rom longitudinal studies which investigated their potential to
redict surrogates outcomes including mortality and lifespan. We
ound that mortality was the ageing-related phenotype most com-
only evaluated for associations with physiological and metabolic
iomarkers and there was good evidence that biomarkers of
Fig. 2. Proposed measurement domains  intervention studies.
cardiovascular function, metabolic processes, inflammation, organ
(e.g. lung) function, and body mass and composition are associ-
ated with ageing phenotypes. For example, of the components
of the Metabolic Syndrome, only raised BP and impaired fasting
glucose concentration are significant predictors of greater mortal-
ity [9]. A difference of 20 mmHg  in Systolic BP (or 10 mmHg  in
Diastolic BP) is associated with more than a twofold difference
in death from several vascular causes [10]. In addition, high BP
in midlife is associated with lower cognitive function in later life
[11]. Markers of dysregulation of glucose metabolism are impor-
tant predictors of mortality [12–15] and poorer glycaemic control
is associated with cognitive impairment even in non-diabetics
[16].
Central adiposity is a risk factor for ageing and for age-related
diseases with the lowest all-cause mortality risk for those with
waist circumferences (WC) of 94 and 77 cm for men  and women,
respectively, and the relative risk (RR) of mortality is doubled
for those with WCs  of 132 and 116 cm in men and women,
respectively [17]. Overall adiposity may  also be important since
each 5 kg/m2 increase in body mass index (BMI) is associated
with 30% higher overall mortality, 40% higher vascular mortality,
60–120% higher diabetic, renal, and hepatic mortality [18]. High
BMI, independent of gender and other confounding factors, is a
risk factor for cognitive decline [19].
In addition, individuals with the lowest Forced Expiratory Vol-
ume  (FEV1) [20], a marker of lung function, have the highest risk of
mortality (RR, 1.99; 95% CI 1.71–2.29). This relationship remained
for the Healthy Ageing Phenotype.
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Table  1
Tools to measure selected domains and sub-domains of the Healthy Ageing Phenotype.
Domain Subdomain Tool/measure
Physiological and metabolic health
Cardiovascular function
Blood pressure
Blood lipids
Lung function
Forced expiratory volume (FEV1)
Blood glucose
Glucose metabolism Glycated haemoglobin (HbA1C)
Body composition
Waist circumference
Waist to hip ratio
Body mass index (BMI)
Physical capability
Strength Handgrip strength
Locomotion Gait speed
Endurance Walk endurance test
Dexterity Pegboard dexterity test
Balance Standing balance test
Cognitive function
Processing speed
Speed reaction time
Symbol digit modalities test
Episodic memory
Story recall
Word list recall
Paired associate learning
Executive function
Stroop
Trail making tests A & B
Psychological wellbeing
Positive and negative affect Positive and negative affect schedule (PANAS)
Life satisfaction Satisfaction with life scale (SWLS)
Quality of life
Control, autonomy, pleasure and self-realization, quality of life scale (CASP-19)
WHO  quality of life-BREF (WHOQOL-BREF)
Mental health
Centre for epidemiological studies depression scale (CES-D)
Warwick-Edinburgh mental wellbeing scale (WEMWBS)
Resilience Psychological resilience scale
Social wellbeing
Social network
Lubben social network scale
NIH Toolbox: friendship
PROMIS: companionship
Social isolation
Social functioning PROMIS: satisfaction with social roles and activities
Perceived emotional/social support
Revised UCLA loneliness scale
Social support behaviours scale
NIH Toolbox: emotional support
Instrumental support
Loneliness
Perceived rejection scale
NIH Toolbox: psychological wellbeing
s
F
a
a
(
1
2
3
4
5
2
h
t
sSense of purpose
ignificant after adjustment for smoking behaviour suggesting that
EV1 is a general biomarker of mortality risk. The evidence for
ssociations of FEV1 with other ageing-related phenotypes such
s cognitive decline is more limited [21].
In summary, the following physiological and metabolic
bio)markers show potential as measures of the HAP (Table 1):
. arterial blood pressure as a measure of cardiovascular function
[10,22];
. fasting glucose and/or glycated haemoglobin (HbA1C) as a
marker of glucose homeostasis [12–15];
. Forced Expiratory Volume (FEV1) [20] as a marker of lung func-
tion.
. waist circumference, waist to hip ratio [17,23,24], or body mass
index [18,25] as a measure of adiposity;
. plasma concentrations of total cholesterol and cholesterol frac-
tions (LDL and HDL cholesterol) [26,27] and triglycerides [28] as
biomarkers of lipid metabolism.
.1. Potential future markers of physiological and metabolic
ealthThere is evidence that other biomarkers of cardiovascular func-
ion such as Fibrinogen [29] and markers of (chronic) inflammation
uch as IL-6 [30] and C-reactive protein (CRP) [31] are associatedMeaning and purpose
with risk of mortality and of age-related disease. However, their
advantages over the better established biomarkers identified above
is still debated. There is also emerging evidence of the poten-
tial importance of more novel biomarkers including 25-hydroxy
cholecalciferol (vitamin D) concentrations [32], Brain Natriuretic
Peptide [33], IGF-1 [34], and Cystatin C [35], which deserve fur-
ther investigation as possible additions to the suite of biomarkers
of physiological and metabolic health useful for characterising and
quantifying the HAP.
There is growing interest in the use of challenge tests to assess
the flexibility of physiological and metabolic systems e.g. the glu-
cose tolerance test is a measure of the individual’s ability to
maintain glucose homeostasis which may  be an advance on the
“static” measurement of fasting glucose concentration. However,
the additional complexity involved in and time required for these
measurements so far have limited their use to laboratory and clini-
cal settings. In some areas, other surrogate measures might fulfil
this role to some extent. For example, glycated haemoglobin it
is an integrated measure of the consequences of excursions in
blood glucose concentration over longish time periods. Challenge
tests targeting important aspects of physiological and metabolic
processes (e.g. inflammation and substrate oxidation) which can
identify early functional decline preceding age-related disease [36]
could lead to more sensitive and/or informative measures of the
HAP.
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. Physical capability
Physical capability has been described by Cooper et al. [37,38]
s the physical or functional capacity of an individual to carry out
uccessfully activities of daily life which, in turn, is an indicator of
ealthy ageing. Capturing physical capability is therefore impor-
ant to inform measures of the HAP. It encompasses a broad range
f physical functions and a plethora of measurement tools are
sed to capture its multidimensional nature, ranging from hand
rip strength to walking endurance. Evidence to support the use
f measures of physical capability as surrogate markers of current
nd future health status is promising. For example, grip strength,
alance, gait speed and chair rise time predict longevity, risk of age-
elated diseases and/or rates of mortality in observational studies
37,39,40].
Although such measures appear simple to use and convenient
or implementation in a wide variety of contexts, there is consider-
ble variation in testing protocols [37,38]. Inconsistent application
nd reporting have led to efforts to harmonise protocols to facilitate
ata capture, reliability and multicentre studies and as the basis for
ossible data pooling across trials. Issues relevant to standardised
ssessment of motor functioning have been addressed recently by
he development of the NIH Toolbox [41]. This Toolbox aims to
efine a standard set of measures that can be used as a “common
urrency” across diverse studies [41] and includes 5 domains and
ssociated tests for assessment of motor function (Table 1). Crite-
ion validity was established for all recommended tests along with
est–retest reliability.
In the present context, the NIH Toolbox offers guidance on stan-
ardising and instrumenting a number of tools within the larger
omain of physical capability. Some commonly used measures are
otably absent such as the timed up and go (TUG) and timed sit-to-
tand tests which are used ubiquitously for assessment of mobility
n older adults. Suitable tests are captured in other NIH domains
42] and should be included within a comprehensive assessment of
hysical capability. While the NIH Toolbox tests have been devel-
ped for use across the lifespan (3–85 years), tests such as the TUG
ave been designed specifically for older adults. In practice the
hoice of test should take into account the age range of interest
nd may  need to incorporate a broader range, or levels of complex-
ty, of tests. Nevertheless the NIH Toolbox is an important start to
rive consistency and which will be strengthened by testing within
arger longitudinal studies.
.1. Potential future markers of physical capability
Looking to the future a number of advances are currently being
mployed, or are in the process of development and validation,
hich will ultimately complement the approaches summarised in
able 1. Recent developments to evaluate physical capacity include
he use of stress tests where protocols are modified to increase
heir difficulty. Such stress tests may  be more sensitive because
hey invoke compensatory strategies which may  be compromised
n those ageing less healthily. An example from the NIH Toolbox is
ait measured at fast walking pace. Other examples include walking
r carrying out a balance task while being distracted by concurrent
econdary task performance, often a cognitive task. Decrement in
erformance under dual-task conditions increases with age and is
xacerbated in at risk populations [43,44].
Advances in technology will drive innovation in methods of
ata collection and contribute novel metrics in two  key areas:
nstrumentation of physical performance testing batteries and
easurement of physical performance and function over extended
eriods in real-world settings [45]. With regard to the former,
nstrumentation of tests using body worn sensors (e.g. accelerome-
ers and gyroscopes) is now possible due to low cost and increased6 (2013) 189– 199 193
analytical methods to derive sensitive physical capability out-
comes [46–51]. Whilst some current methods remain complex,
difficult and time consuming to derive (e.g. patterns), ultimately
this approach will bring considerable advantages related to accu-
racy of recording, extraction of metrics with increased sensitivity
and ease of data collection in a wide variety of environments. On the
basis of previous work, current developments and future potential,
we make the following recommendation: five subdomains, which
are also recommended in the NIH Toolbox tests, should be used
to assess physical capability. Further evidence is needed on the
predictive power of other tests which at present are relevant to
populations over 70 years of age e.g. timed up and go (TUG) and
timed sit to stand tests.
4. Cognitive function
Numerous facets of cognitive processing decline over the later
stages of adult lifespan [52], and thus offer potential as markers
of healthy cognitive ageing that can be targeted in intervention
studies. However, psychometric measures of these so-called ‘fluid’
[53] cognitive abilities are often highly correlated with one another
[54], indicating that patterns of cognitive change can be explained
with reference to a smaller set of more fundamental functions.
One function that accounts for much of the variance seen
in other cognitive tasks, and thus offers an efficient measure of
overall functioning, is ‘cognitive processing speed’ [54]. Measures
of cognitive processing speed, such as visual inspection time or
speeded reaction time [55], predict morbidity and mortality [56];
are responsive to physical activity interventions [57]; and correlate
with performance-based measures of everyday functioning [58],
demonstrating their validity as indices of healthy ageing. Many
processing speed tasks also benefit from very simple task instruc-
tions, and rely on differences in speed rather than accuracy to
judge ability. This can make them more acceptable and less anxiety-
provoking for participants compared with tasks in which errors are
frequent and more salient.
Other cognitive functions that likely make unique contributions
to patterns of overall cognitive change with age, include episodic
memory [54] and aspects of executive function [59]. Indices of
memory and executive functioning are also of particular signifi-
cance to cognitive health in later life and deficits in these areas are
characteristic of Alzheimer’s disease [60] and other forms of later-
life dementia [61]. The addition of such measures to a battery of
cognitive tests was  therefore considered likely to provide a broader
index of overall cognitive health. However, Workshop participants
recognised the difficulty of treating ‘executive function’ as a sin-
gle domain, when it is likely comprised of several subdomains that
may  be affected differentially by age and health interventions.
4.1. Tools to measure the cognitive function component of the
HAP
Opinions vary amongst researchers regarding the most appro-
priate tools with which to measure these domains of cognitive
function over time, and Workshop participants felt that it would be
difficult to reach consensus on a single battery suitable for all inter-
vention studies. Nevertheless, several considerations can be used
to guide test selection. First, practice effects should be minimised
by e.g. using random stimulus generation or alternative equiva-
lent versions of the test. Tests should not show floor or ceiling
effects in the population being considered, and should be robust to
the effects of different administrators. Where possible, alternative
stimulus presentation and response modes (e.g. auditory as well as
visual presentation; verbal as well as button press response) should
also be available to maximise the inclusion of participants with
physical or sensory impairments. Finally, if using computerised
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ssessments rather than traditional ‘pen and paper’ tests, Work-
hop participants recommended that researchers should select
ests that are supported by on-going technical development to
ncrease the likelihood that they will be ‘future-proof’ against
dvances in operating systems and computer hardware. Some
xamples of suitable tools for measuring each of the domains are
resented in Table 1. Details of these tools can be found in Lezak
t al. [62].
.2. Prior cognitive ability
Measures of ‘crystallised’, knowledge-based abilities, such as
ocabulary [63], as well as indices of educational achievement
orrelate with levels of prior cognitive ability [64]. These measures
an therefore be useful for determining the extent or rate of cog-
itive decline that an individual has already experienced before
aking part in an intervention. Such measures are particularly
mportant when selecting participants for interventions targeted
owards particular stages or levels of cognitive decline, or when
nvestigating the absolute effect of an intervention on overall
evels of cognitive ageing.
.3. Subjective ratings of cognitive ability
Other contextual data regarding cognitive health that are poten-
ially useful include participants’ subjective ratings of their own
ognitive ability [65]. We  recognise that subjective ratings show
elatively weak correlation with objective measures of current or
uture cognitive ability, and are often influenced by other variables
elating to mood, personality, and mental health [66]. However,
ubjective perceptions of cognitive ability may  be particularly
mportant in the context of lifestyle-based intervention studies,
n which participants’ goals and motivation for undertaking and
dhering to the intervention may  be influenced by their own  view
f how successfully they are ageing, or how effective they perceive
he intervention to be.
. Psychological and subjective wellbeing
Psychological wellbeing (PWB) and subjective wellbeing
SWB) do not decrease significantly over later adulthood, despite
ncreased physiological and cognitive dysregulation. The trajec-
ory of this so-called ‘wellbeing paradox’ is likely underpinned by
trategic shifts in individuals’ self-regulation to accommodate the
dditional challenges of ageing [67]. Phenotypic markers of healthy
geing, therefore, should ideally include both wellbeing outcomes
nd indices of the optimally-adaptive mechanisms through which
hey arise.
PWB  and SWB  comprise complementary but distinct self-
eported aspects of what it means to age well. SWB, the personal
xperience of evaluating life in positive terms, includes elevated
ositive affect (PoA), low negative affect (NeA) and high levels of
ife satisfaction. PWB  consists of successful engagement with the
evelopmental and existential challenges of later life i.e. challenged
hriving [68]. Large-scale population data support the separability
f the two overarching domains, whilst qualitative data indicate
hat older adults afford many of the components of PWB  and SWB
riority over physiological function in their conceptualisations of
ealthy ageing [69].
There is strong evidence for the validity of SWB  as a marker
f healthy ageing. Meta-analyses show that measures of PoA and
eA respond favourably to physical activity interventions in older
dults [70]. PoA, NeA and life satisfaction are also associated with
elf-perceived health in older adults and predict subsequent mor-
ality and morbidity irrespective of initial health status [71]. Several
ools which capture the components of SWB  can detect change
n response to interventions with older adults, and have good6 (2013) 189– 199
psychometric credentials. These include Diener et al. Satisfac-
tion With Life Scale [72] and the Life Satisfaction Index Z [73].
Although single-item measures of global life satisfaction have been
included in numerous population-level surveys, discussants at the
Workshop concluded that they lack the sensitivity and conceptual
specificity required for use in intervention studies.
The components of PWB, as proposed by Ryff [74], have received
considerable research attention as markers of healthy ageing.
Autonomy, self-acceptance, environmental mastery, purpose in
life, personal growth and positive relations with others all con-
tribute to successful thriving in the face of age-related challenges.
Meta-analyses indicate that the Scales of Psychological Wellbeing
[74,75] respond to lifestyle interventions [76] and, like SWB, pre-
dict mortality, morbidity and institutionalisation [77]. Workshop
discussants agreed that Ryff’s scale benefits from an explicit theo-
retical foundation in social gerontology and sound psychometric
credentials, but noted that its length might affect negatively its
feasibility and acceptability in large-scale intervention studies, and
that its multidimensional factor structure has been questioned [78].
Resilience, the “process of negotiating, managing and adapt-
ing to significant sources of stress or trauma”, is a concept closely
related to PWB  [79]. Resilience appears to provide a roadmap to suc-
cessful adaptation to developmental challenges in healthily ageing
adults; in this respect it may  be a distinct marker of healthy ageing.
However, measurement of resilience is in its infancy and Work-
shop discussants concluded that evidence of the responsiveness
of resilience measures to public health interventions is suggestive
rather than decisive [79]. Currently, Windle, Markland and Woods’
[80] psychological resilience scale appears best suited as an out-
come measure for healthy ageing interventions, due to the large,
non-clinical sample of adults aged 40–90 years used in its devel-
opment and its strong conceptual origins. More broadly, the case
of resilience also highlights the fact that psychological markers of
healthy ageing are often also understood as process variables by
which healthy ageing is sustained i.e. causality is not unidirectional.
5.1. Tools to measure the psychological wellbeing component of
the HAP
Current knowledge of PWB  and SWB  in healthy ageing is con-
strained by the varied and inconsistent ways in which researchers
have selected wellbeing tools, some of which bear little or no
specified relation to theory. Absence of mental health problems is
not synonymous with either PWB  or SWB, and Workshop discus-
sants recommended that both domains be captured when assessing
intervention efficacy. The four key principles we  identify in Section
6 of this paper on ‘Social wellbeing’, provide additional guidance
on the process of tool selection. As an extension of these prin-
ciples, we recommend that investigators using PWB  and SWB
as markers of healthy ageing be explicit when describing the
component(s) of wellbeing that they seek to measure in light of
theory, and provide a brief rationale for selecting both this com-
ponent and their tool of choice. Following a systematic literature
review and an iterative mapping exercise to link extant tools
with key wellbeing domains, suggestions for measurement are
summarised in Table 1 [72,80,113–117]. Recent innovations in eco-
logical momentary assessment methods, which involve repeatedly
sampling participants’ experiences in real time and in real-world
settings, may  be used to capture intra-individual variability in psy-
chological wellbeing with maximal ecological validity and minimal
recall bias [81].5.2. Subjective ratings of physical and emotional health
Workshop discussants also noted that, compared with objective
functional data, subjective ratings of health are superior predictors
ritas 7
o
o
h
a
u
r
a
m
t
v
h
6
p
i
t
‘
c
t
c
w
t
a
m
b
s
t
[
i
d
r
r
a
t
c
i
m
b
a
v
h
t
o
a
e
p
w
o
c
i
i
s
r
f
c
t
o
o
s
s
i
oJ. Lara et al. / Matu
f both SWB  and subsequent mortality [82]. As a sensitive index
f subjectively-rated health, the SF-36 is particularly popular, and
as been used widely in intervention studies with healthy older
dults. However, the SF-36 does not have its basis in theoretical
nderstandings of either SWB  or PWB  and so is frequently misrep-
esented as a measure of wellbeing itself. Despite this limitation,
long with measures of perceived cognitive function, the SF-36
ight be used to examine the extent to which declines in par-
icipants’ subjective functioning presage the onset of objectively
erifiable functional declines, as a potential early indicator of non-
ealthy ageing.
. Social wellbeing
Good health and wellbeing in later life extends beyond issues of
hysiological functioning to include social factors such as engaging
n supportive and rewarding relationships and having opportuni-
ies to explore personal interests. This conceptualisation of ageing
well’ is both intuitive and embedded in the empirical and theoreti-
al research literature [5,83–85]. ‘Social wellbeing’ – as an umbrella
erm for social relationships and personal development – is a key
omponent of a number of models of ageing [5,86–91]. However
hilst ‘social wellbeing’ is also widely recognised as an impor-
ant outcome, a definition remains elusive and the absence of an
greed definition limits the ability to develop tools suitable for its
easurement.
Factors that contribute to ‘social wellbeing’ in later life have
een defined and measured in numerous ways, for example as
ocial integration [92], social engagement [93–97] social participa-
ion [98], social networks [99], social ties [100], social connections
101] and social connectedness [102]. Studies of these concepts,
ncluding a meta-analysis of the impact of social relationships
efined more broadly, suggest that maintaining active social
elations in later life is associated with better health outcomes and
educed mortality [94,98,99,101,103,104]. However, the specific
spects of social wellbeing that are conceptually important, and
hose that are amenable to intervention, remain unclear. In the
ontext of the development of the HAP, this conceptual diversity
s a further significant barrier to the identification of appropriate
easurement tools.
Within the LiveWell programme we investigated social well-
eing through the pursuit of 3 explicit objectives: (i) to identify
n appropriate question for a systematic review of ‘social inter-
entions’ with health and wellbeing outcomes; (ii) to understand
ow people moving through a retirement transition understood
he term ‘wellbeing’, and how they experienced variations in their
wn wellbeing; (iii) to identify appropriate outcome measures to
ssess the effectiveness of lifestyle interventions.
To meet the first objective, we scoped the literature to gen-
rate a list of key concepts relating to social wellbeing and older
eople, then – through a series of small workshops – worked
ith local experts to refine the list and generate an agreed set
f ‘core’ conceptual components constituting social wellbeing. The
omponents were refined iteratively and used as a ‘filter’ to help
dentify gaps in the literature through which we were able to
dentify a suitable question for systematic review. To meet our
econd objective, we undertook a qualitative study of the expe-
iences of people in retirement transition. We  used early findings
rom the qualitative study to inform further development of our
ore set of conceptual components of social wellbeing. In working
owards the third objective, we applied the conceptual components
f social wellbeing to outcomes reported in studies included in
ur systematic review [105] and the broader literature previously
coped. We  used the concepts as a ‘filter’ to identify relevant mea-
urement tools. We  were guided in this task by investigating the
ntended conceptual target of the tool as reported by its author
r by the author of the study reporting its use (as appropriate), in6 (2013) 189– 199 195
addition to our own  judgement. We tabulated the range of con-
ceptual categories, the tools used to measure them (as reported
in the literature), and the methods through which we identified
the tools (e.g. systematic review or convenience sample). A more
detailed explanation of our methods and outcome is being prepared
for publication.
The roundtable discussion at the Workshop was  divided into
two halves. In the first half the group discussed general conceptual
issues regarding measurement of social and psychological con-
cepts. The aim of this discussion was  to identify the most adequate
measures of ‘healthy ageing’ with respect to psychological and
social wellbeing. Four key principles for the selection of measures
were identified:
1. Identification of a minimal set of scales of mutually exclu-
sive constructs. One suggested approach was to map  existing
measures onto the results of the completed qualitative work
described earlier (publication of the qualitative work is currently
in progress) and its evolved concepts.
2. Assessment of the acceptability of the measures by the specific
population under study.
3. The most relevant measures will be those with the robustness
and sensitivity to measure change in this aspect of the HAP in
response to a lifestyle-based intervention.
Wellbeing outcome variables should differ conceptually from the
core behaviours that an intervention seeks to modify, and from the
moderators and mediators from which they are hypothesised to
arise.
Two  possible development pathways for the social well-
being component of the HAP were identified. The first was  to
develop integrated social and psychological wellbeing components
through a concept mapping exercise, identifying relevant concepts
from: a systematic review of the topic ‘wellbeing’ in our target
population, terms identified through the previous card sorting
activities, and the qualitative work cited above. Appropriate out-
come measures would be identified by applying HAP criteria to
the concepts, then matching each concept to suitable measure-
ment instruments. The second approach suggested was  to draw
on work already conducted in development of the NIH Toolbox
[106] where components within the ‘emotion’ domain (specifi-
cally: life satisfaction; meaning; social support; companionship;
social distress; positive social development; and social network
integration) may  be compatible with the social wellbeing compo-
nents of the HAP. However, norms for NIH Toolbox instruments
were derived from the general population including children and
young adults, and their appropriateness for measuring the well-
being of people in the peri-retirement life stage has not been
established.
The decision to pursue a rigorous concept mapping process in
order to identify relevant measurement instruments was taken
by the team. Subsequently two hundred and ninety eight terms
were printed on individual cards and sorted into loose concep-
tual categories by three members of the research team across three
meetings. Decisions regarding the categories were reached through
debate between the team members and all decisions and under-
pinning rationale were logged. In total this mapping process took
eight hours to complete. The work of matching conceptual cate-
gories and specific constructs to outcome measures is on-going.
Some potentially appropriate measurement tools are presented in
Table 1.
7. Concluding remarksIn the context of lifestyle-based intervention studies designed
to enhance healthy ageing, there is need for a panel of measure-
ments which captures and quantifies features of the HAP that
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re objectively important (predict the ageing trajectory) and for
hich there are tools that are sufficiently sensitive to have utility
s outcome measures. Our work on this issue is limited by both
onceptual and practical problems. In particular, we are trying to
easure something (healthy ageing) which has yet to be defined
dequately and, as a consequence, we have had to use information
rom studies using (inadequate) surrogates such as mortality or
ifespan. Nevertheless, we have suggested, tentatively, 5 domains
iz. (1) physiological and metabolic health, (2) physical capability,
3) cognitive function, (4) psychological wellbeing, and (5) social
ellbeing which collectively may  provide a reasonably holistic
ssessment of the HAP. We  then attempted to identify key sub-
omains within each of these 5 main domains and tools for their
easurement. In some domains e.g. cognitive function, there was
ood agreement about the key sub-domains but debate about the
ppropriate tools for their quantification. In contrast, selection of
easurement domains is less well developed in other areas e.g.
ocial wellbeing (where the definition of the concept itself remains
lusive) and this has implications for the identification and devel-
pment of appropriate tools. Our research did not consider all
ossible components of the HAP and e.g. we did not address the
enses (taste, vision, smell, hearing and somato-sensation related
omains). It is well-established that acuity of these senses declines
ith age and that lifestyle-based intervention may  modulate this
ge-related decline see e.g. Richer et al. [107]. However, it remains
o be established whether change in sense acuity is an independent
redictor of the ageing trajectory (or simply a fellow traveller) and
o whether this domain should be included within the HAP. In the
vent of their inclusion, the NIH Toolbox provides protocols for
heir assessment [108–110,47,111,112].
Research on conceptualisation of the HAP and on the develop-
ent of tools for its measurement is in its early stages. We  believe
hat such research is timely and has the potential to benefit from
dvances in other fields. For example, innovations in the develop-
ent of body worn sensors (allowing higher sampling frequencies
nd greater data storage capabilities) together with algorithms for
nterrogation of the resulting data are likely to provide the basis for
uch more informative measures of physical capability. Challenge
ests offer the promise of more sensitive measures of physiological
nd metabolic health whilst stress tests may  be the basis for bet-
er measures of both physical and cognitive function. The priority
hould be to develop test protocols which (i) are acceptable to older
articipants, (ii) can be deployed in community settings, (iii) have
ow costs in terms of skills and resources, (iv) are relatively quick to
omplete (to minimise both researcher and participant burden) and
v) are capable of measuring change in response to lifestyle-based
ntervention.
Although the research summarised in this Workshop report had
ery utilitarian objectives, it may  have some value in helping to
onceptualise the HAP. In addition, we hope that these tentative
roposals will encourage other researchers to test their utility and
o add to, or subtract from, the domains and tools summarised in
able 1.
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